Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 277-288

  Okarvi, Subhani M ^a   Al Jammaz, Ibrahim ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Biodistribution; Bombesin; Cell binding; Cytotoxic peptide; Methotrexate; Radiolabeling; Technetium 99m

Indexed keywords

BOMBESIN; BOMBESIN RECEPTOR; CYSTEINE; GASTRIN RELEASING PEPTIDE; HISTIDINE; METHOTREXATE; METHOTREXATE BOMBESIN TC 99M CONJUGATE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CHELATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LIPOPHILICITY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; RAT; SOLID PHASE SYNTHESIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NEOPLASMS; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TECHNETIUM; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77950296961     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.12.006     Document Type: Article

References (46)

1. Anastasi A., Erspamer V., Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971, 27:166-167.
2. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 2002, 43:1650-1656.
3. Shipp M.A., Tarr G.E., Chen C.Y., Switzer S.N., Hersh L.B., Stein H., et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A 1991, 88:10662-10666.
4. Faintuch B.L., Teodoro R., Duatti A., Muramoto E., Faintuch S., Smith C.J. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008, 35:401-411.
5. 2 or its derivatives. Proc Natl Acad Sci U S A 1994, 91:12664-12668.
6. Nakagawa T., Hocart S.J., Schumann M., Tapia J.A., Mantey S.A., Coy D.H., et al. Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). Biochem Pharmacol 2005, 69:579-593.
7. 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007, 18:1110-1117.
8. Smith C.J., Volkert W.A., Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 2005, 32:733-740.
9. Fleischmann A., Waser B., Gebbers J.O., Reubi J.C. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. J Clin Endocrinol Metab 2005, 90:4722-4729.
10. Fleischmann A., Läderach U., Friess H., Buechler M.W., Reubi J.C. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000, 80:1807-1817.
11. 14] bombesin(6-14). Clin Cancer Res 2002, 8:1139-1146.
12. 2 structural paradigm in a prostate cancer model. Bioconjug Chem 2008, 19:1803-1812.
13. Zhang H., Chen J., Waldherr C., Hinni K., Waser B. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides with indium-111, leutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
14. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 2008, 34:13-26.
15. Schally A.V., Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003, 72:2305-2320.
16. Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
17. Nagy A., Armatis P., Cai R.Z., Szepeshazi K., Halmos G., Schally A.V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A 1997, 94:652-656.
18. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006, 47:1144-1152.
19. Mantey S.A., Weber H.C., Sainz E., Akeson M., Ryant R.R., Pradhan T.K., et al. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 1997, 272:26062-26071.
20. Pradhan T.K., Katsuno T., Taylor J.E., Kim S.H., Ryan R.R., Mantey S.A., et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 1998, 343:275-287.
21. Nagy A., Szoke B., Schally A.V. Selective coupling of methotrexate to peptide hormone carriers through a γ-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling. Proc Natl Acad Sci 1993, 90:6373-6376.
22. Bertino J.R. Ode to methotrexate. J Clin Oncol 1993, 11:5-14.
23. 111In-DTPA-methotrexate. Cancer Biother Radiopharm 1998, 13:177-184.
24. Reubi J.C., Mäcke H.R., Krenning E.P. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005, 46:67S-75S.
25. Grant G.A. Synthetic peptides 2002, Oxford University Press, New York.
26. Okarvi S.M. Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent. J Peptide Res 2004, 63:460-468.
27. Stalteri M.A., Bansal S., Hider R., Mather S.J. Comparison of the stability of technetium-labeled peptides to challenge with cysteine. Bioconjug Chem 1999, 10:130-136.
28. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002, 13:530-541.
29. Okarvi S.M., Jammaz I.A. Preparation and in vitro and in vivo evaluation of technetium-99-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm 2006, 21:49-60.
30. 4. Anal Sci 2007, 23:151-155.
31. Nakao R., Furutsuka K., Yamaguchi M., Suzuki K. Sensitive determination of specific radioactivity of positron emission tomography radiopharmaceuticals by radio high-performance liquid chromatography with fluorescence detection. Nucl Med Biol 2008, 35:733-740.
32. 11C]DASB for measuring endogenous serotonin with PET: binding studies. Nucl Med Biol 2005, 32:129-136.
33. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989, 49:6352-6358.
34. Guide for the Care and Use of Laboratory Animals 1996, National Academy Press, Washington, DC.
35. Mather S.J., Ellison D., Bard D.S. Technetium-99m labelled hybrid receptor-binding peptides. Technetium and rhenium in chemistry and nuclear medicine 1995, 491-497. SG Editoriali, Padova (Italy).
36. Lister-James J., McBride W.J., Buttram S., Civitello E.R., Martel L.J., Pearson D.A., et al. Technetium-99m chelate-containing receptor-binding peptides. Technetium and rhenium in chemistry and nuclear medicine 1995, 269-274. SG Editoriali, Padova (Italy).
37. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33:371-380.
38. Hoffman T.J., Smith C.J. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol 2009, 36:579-585.
39. Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995, 55:280-287.
40. Giacchetti S., Gauvillé C., De Crémoux P., Bertin L., Berthon P., Abita J.P., et al. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer 1990, 46:293-298.
41. 4) bombesin by tumor cells. Prostate 1994, 25:29-38.
42. Horne D.W., Reed K.A. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001, 394:39-44.
43. Deutsch J.C., Elwood P.C., Portillo R.M., Macey M.G., Kolhouse J.F. Role of the membrane-associated folate binding protein (folate receptor) in methotrexate transport by human KB cells. Arch Biochem Biophys 1989, 274:327-337.
44. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
45. De Jong M., Krenning E.P. Molecular imaging and therapy of cancer using radiolabelled peptides. EJHP 2005, 01:20-21.
46. Rolleman E.J., Valkema R., de Jong M., Kooij P.P.M., Krenning E.P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003, 30:9-15.